The current business model for antibiotics is plagued by market failures and perverse incentives that both work against conservation efforts and provide insufficient rewards to drive the development of much-needed new treatments ...
Jun 14, 2016
0
0
(HealthDay)—Direct primary care, where doctors bypass insurance companies, is an emerging business model, according to an article published in The Boston Globe.
Apr 26, 2016
0
1
Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, ...
Jul 1, 2014
0
0
In a sting operation, John Bohannon, a correspondent of Science, claims to have exposed dodgy open access journals. His argument seems to be that, because of their business model, some journals are biased towards accepting ...
Oct 4, 2013
0
0
Will 2014 mark the beginning of the end for employer-sponsored health insurance as we know it?
Sep 10, 2013
0
0
An initiative from the drugs regulator, the European Medicines Agency, to commit to releasing all of the information from clinical trials once the marketing authorization process has ended, which has been greeted with cautious ...
Jan 29, 2013
0
0
(HealthDay)—Physician business models are transforming, with a sustained shift away from independent practice, according to report released by the consulting firm Accenture.
Dec 11, 2012
0
0
They say the real crisis stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.
Aug 7, 2012
0
0
BioMed Central's open access journal BMC Medicine adds scientific rigour to the debate about open access research, by publishing an article which compares the scientific impact of open access with traditional subscription ...
Jul 16, 2012
0
0
